share_log

Cantor Fitzgerald Reiterates Overweight on Connect Biopharma Hldgs, Maintains $5 Price Target

Cantor Fitzgerald Reiterates Overweight on Connect Biopharma Hldgs, Maintains $5 Price Target

坎托·菲茨杰拉德重申增持Connect Biopharma Hldgs,维持5美元的目标股价
Benzinga ·  2023/09/13 08:24

Cantor Fitzgerald analyst Louise Chen reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight and maintains $5 price target.

Cantor Fitzgerald分析师Louise Chen重申康乃德生物(纳斯达克:CNTB)增持,并维持5美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发